Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Assets (2016 - 2025)

Voyager Therapeutics' Other Non-Current Assets history spans 11 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 4.8% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, down 4.8%, while the annual FY2025 figure was $2.7 million, 4.8% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.7 million at Voyager Therapeutics, down from $5.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.6 million in Q3 2025 and bottomed at $1.5 million in Q2 2022.
  • The 5-year median for Other Non-Current Assets is $2.0 million (2021), against an average of $2.3 million.
  • The largest annual shift saw Other Non-Current Assets crashed 32.58% in 2022 before it soared 95.34% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.8 million in 2021, then decreased by 14.84% to $1.5 million in 2022, then grew by 5.15% to $1.6 million in 2023, then soared by 80.41% to $2.9 million in 2024, then fell by 4.8% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Other Non-Current Assets are $2.7 million (Q4 2025), $5.6 million (Q3 2025), and $2.9 million (Q2 2025).